ISU ABXIS

ABXIS DREAM

ISU ABXIS endeavors in making the future without
incurable diseases with Isu’s biotechnology and passion.

ISU ABXIS is continuously striving to provide better treatment options
for patients suffering from difficult-to-treat diseases based on
Isu’s excellence in biotechnology.

Bio medicine business

ISU ABXIS is a leading company in bio medicine development based on genetic recombination technology focusing on rare medicine development which is showing high growth rate.

ISU ABXIS

ISU ABXIS is the leading company in orphan drug development by succeeding the orphan product launches for Gaucher’s and Fabry’s diseases.

Abcertin imiglucerase

Abcertin imiglucerase
Abcertin^® is the orphan drug used in long term enzyme replacement therapy (ERT) for patients with Gaucher’s disease.

Fabagal agalsidase beta

Fabagal agalsidase beta
Fabagal^® injection is the orphan drug used for long term enzyme replacement therapy (ERT) for patients with Fabry’s disease.

Clotinab abciximab

Clotinab abciximab
Clotinab^® is the antibody treatment used to prevent ischemic heart complications in high risk patients during percutaneous transluminal coronary angioplasty (PTCA).